Consumer Medicine Information (CMI) about Sacubitril/Valsartan Alphapharm intended for persons living in Australia.

Sacubitril/valsartan treatment is currently indicated in all symptomatic patients with heart failure with an ejection fraction ≤35% already treated with a β-blocker and an ACEi or ARB. 19 However, no ...

We evaluated the cost-effectiveness of sacubitril/valsartan (formerly LCZ696) compared with an ACE inhibitor (ACEI) (enalapril) in the treatment of HF-REF from the perspective of healthcare providers ...

Valsartan Valsartan (Diovan, Novartis) was the second nonpeptide AT-II type 1- receptor antagonist available for the treatment of hypertension. Valsartan is rapidly absorbed from the ...